Gilyazova, I.,
Ivanova, E.,
Pavlov, V.,
Khasanova, G.,
Khasanova, A.,
Izmailov, A.,
Asadullina, D.,
Gilyazova, G.,
Wang, G.,
Gareev, I.,
Beylerli, O. (2023) with
complications included 84 patients. Blood samples from patients
with HFRS for molecular genetic analysis were
complications. Interconnected molecular pathways, such as oxidative stress, and the formation of advanced
Buzaev, Igor V.,
Galimova, Rezida M.,
Nabiullina, Dinara I.,
Illarioshkin, Sergey N.,
Zagidullin, Naufal Sh.,
Safin, Shamil M. (2023) .04). No
complications were observed at 6 months. Conclusions: We developed a feasible and safe methodology
that
complicates the course of other concomitant diseases, and predicting the threat of its occurrence